

SUPPLEMENT TO THE PROSPECTUS

This is a supplement to the prospectus dated 5 August 2008 (the "**Prospectus**") made available for distribution by Solvay Pharmaceuticals NV ("**Solvay Pharmaceuticals**") a Belgian company (naamloze vennootschap) with registered office at Gewijde Boomstraat, 21, 1050 Brussels and a wholly owned subsidiary of Solvay NV, in respect of the voluntary and conditional higher takeover bid in cash possibly followed by a public squeeze-out bid on all the shares, warrants and convertible bonds of Innogenetics NV, a Belgian corporation (naamloze vennootschap) with registered office at Technologiepark 6, 9052 Gent, not yet held by Solvay Pharmaceuticals or its affiliated persons.

On 18 August 2008, Innogenetics NV published its half year 2008 results. These results were included in this supplement to the Prospectus.

On 19 August 2008, the Dutch version of this supplement to the Prospectus was approved by the Banking, Finance and Insurance Commission (CBFA) in accordance with Article 17 §2 of the Takeover Act. The CBFA's approval does not imply any judgment on the merits or the quality of the takeover bid or on the position of the persons making the takeover bid.

This is a translation into English of the Dutch original. Only the Dutch original is legally binding. Solvay Pharmaceuticals has performed and assumes responsibility for the English translation.

Solvay Pharmaceuticals, represented by its board of directors, assumes responsibility for the content of this Prospectus as supplemented by this Supplement in accordance with Article 21 of the Takeover Act, except with regard to the reply memorandum (*memorie van antwoord*) drafted in accordance with Articles 22 through 30 of the Takeover Act and included in this Prospectus under Exhibit 3. Solvay Pharmaceuticals declares that the information contained in this Prospectus as supplemented by this Supplement is, to its knowledge, in accordance with the facts and contains no omission likely to affect its import.

The information contained in this Prospectus and this Supplement with regard to the Innogenetics group is based solely on publicly available information, the advice of the board of directors of Innogenetics in accordance with Article 24, §1,1° of the Takeover Act and certain confidential information that Innogenetics made available to Solvay Pharmaceuticals prior to the date of the Prospectus but which according to Innogenetics does not constitute any inside information that needs to be made public in accordance with Article 10 of the law dated 2 August 2002 on the supervision of the financial markets and the financial services.

On 21 August 2008 a notice was published in the Belgian financial press announcing the availability of this Supplement and indicating where and how the Supplement is available. This Supplement constitutes an integral part of the Prospectus. As from this date the Prospectus will not be distributed without this Supplement.

The Prospectus (including the reply memorandum and this Supplement) is available in Dutch and English. A summary of the Prospectus is also available in French. This Prospectus will be made available at no cost at the registered office of Solvay Pharmaceuticals or can be requested by phone at +32 2 229 64 46 (Petercam), +32 800 90 301 (Fortis Bank), +32 3 283 29 70 (KBC Bank) and +32 800 92 020 (CBC Banque). Subject to certain conditions, this Prospectus is also available on the internet on the following websites: www.petercam.be, www.solvay.com, www.fortisbanking.be/saveandinvest, www.kbcsecurities.be, www.kbc.be and www.cbc.be.

Adviser to the bidder
and centralising agent

PETERCAM

Receiving agents

Fortis Bank

Petercam

KBC Securities
in collaboration with
KBC Bank
CBC Banque

19 August 2008

Financial Information on Innogenetics

On 18 August 2008, Innogenetics reported its half year 2008 results as follows:

Innogenetics reports results for the first half 2008. Consolidated revenues up 12% - Gross profit up 16%

Stronger focus towards diagnostic core products

Offer period from August 12 until September 5

Regulated Information¹

Gent (Belgium) - August 18, 2008 – 17h40 (CET)

In the first half year ending June 30, 2008, consolidated revenues² increased by 12% to EUR 30.6 million (H1 2007: EUR 27.4 million). Product sales rose 8% from EUR 25.5 million to EUR 27.6 million, and the gross profit was EUR 17.9 million compared to EUR 15.4 million in the same period last year. Diagnostic product sales increased 8% to EUR 25.8 million (H1 2007: EUR 23.8 million) driven by increased focus on core diagnostic products in infectious diseases and neurodegeneration. Operating loss from recurring operations during the first half year amounted to EUR 3.5 million compared to a loss of EUR 7.0 million in the first half of 2007. In line with the Company's strategy, GENimmune's therapeutic activities were terminated, resulting in non-recurring restructuring and impairment losses amounting to EUR 8.0 million, which led to a consolidated operating loss of EUR 11.5 million. The litigation with Abbott was successfully concluded and all cash was received in the first half of 2008. Solvay announced an offer to acquire Innogenetics for EUR 6.50/share. The offer period³ runs from August 12 until September 5. Innogenetics' Board of Directors considered the offer to be friendly and supports it⁴.

Christiaan De Wilde, CEO of Innogenetics, commented: *"Our continued efforts on cost control, efficiency, and focus towards core diagnostic products is starting to pay off and underpinned our strong sales growth in the first half of 2008. Following the closure of GENimmune, Innogenetics is now fully dedicated to diagnostics. Next to clinical diagnostics we will continue to collaborate with pharmaceutical companies as shown by the agreement in the field of HPV with GlaxoSmithKline. We will exploit the area of companion diagnostics, a field in which Innogenetics and its employees are widely recognized for their leadership."*

First half 2008 – Management's interim report

Consolidated revenues grew 12%, driven by increased product sales and the license fee income from Abbott. An operating loss of EUR 11.5 million was reported. Excluding restructuring and impairment losses the consolidated recurring loss from operations was EUR 3.5 million. The consolidated net loss was EUR 8.0 million compared to a loss of EUR 7.8 million last year. The first half of 2008 resulted in a (basic/diluted) loss per share of EUR 0.26 compared to a loss per share of EUR 0.25 in the same period last year.

The balance sheet contained EUR 15.7 million cash at the end of June 2008, an increase by EUR 2.5 million compared to the end of the first quarter 2008. The cash position at the end of the first half 2007 was EUR 37.4 million. The value of intangible assets, plant property and equipment decreased by EUR 7 million mainly due to the termination of the therapeutic activities of GENimmune.

Cash out flow for the first six months of 2008 was EUR 7.8 million compared to EUR 15.6 million in the same period of last year, excluding the net proceeds from the issuance of the convertible bond. In the first half of 2008, the consolidated operating activities generated EUR 0.7 million cash.

Business update Diagnostics

In the first half of 2008 revenues in Diagnostics increased by 12.3% to EUR 28.8 million. Diagnostic product sales increased by 8.4% to EUR 25.8 million, driven by sales in the areas of infectious diseases (+19%) and Alzheimer's disease (+34%). In the second quarter of 2008, the product sales grew by even 9.5% compared to the same period last year. Growth in infectious diseases area was supported by continued strong HCV genotyping sales in the US and confirmation products in Eastern Europe. Sales in HLA declined slightly due to competitive pressure. Sales in the affiliates grew across the board. US sales (+7%) were affected by unfavourable exchange rates. In local currency (US dollar) the revenue in the US grew by 24%. Overall the negative dollar impact was 1.2% on diagnostic products sales. The Company anticipates that the growth in diagnostic product sales of the first half may not be sustainable in the second half of 2008 based on historical trends that show a lower business activity level for the

third quarter.

The gross margin in Diagnostics was 54.6% from 55.7% in the corresponding six months last year. The combined license and royalty income increased 60% due to license fee income recorded from Abbott. The overall result was an improved gross profit, which rose by 13.1% to EUR 17.1 million compared to EUR 15.2 million in the first half of 2007. R&D expenses in Diagnostics decreased from EUR 7.6 million in the first half 2007 to EUR 6.0 million in the first half 2008. Operating expenses in Diagnostics totalled EUR 10.5 million. Taking into account the positive one-time effects in administration expenses during the first half of 2007 for a total of EUR 3.0 million, the operating expenses in the first half of 2008 decreased by 8% compared to those actually incurred in the corresponding period in 2007. Diagnostics reported a net income of EUR 0.9 million, and an EBITDA margin of 16% on diagnostic product sales.

The HCV genotyping patent litigation against Abbott was successfully concluded following appeal. Abbott subsequently signed a USD 9.5 million settlement and licensing agreement, thereby becoming an additional diagnostics company to acquire a license to Innogenetics' important patent portfolio in the field of hepatitis C.

On June 2, Innogenetics announced the CE marking for its new and expanded HPV genotyping test, the INNO-LiPA HPV Genotyping Extra. The new generation kit allows the genotyping of 28 different HPV genotypes, of which 18 are high-risk types for the possible development of cervical cancer. The test is based on Innogenetics' patent-protected SPF10 primers.

Business update Therapeutics

Innogenetics definitively terminated the therapeutic activities of GENimmune, which resulted in EUR 8.0 million non-recurring restructuring and impairment losses. GENimmune's contract manufacturing unit was re-integrated within Innogenetics N.V. and recorded EUR 1.8 million in revenue in the first half of 2008.

Solvay's friendly bid to acquire Innogenetics

On April 25, Innogenetics and Solvay jointly announced the launch of a friendly offer by Solvay to acquire Innogenetics. Solvay Pharmaceuticals, a subsidiary of Solvay SA (NYSE Euronext: SOLB), has launched this public takeover bid to acquire all outstanding shares, warrants, and options of the Company. The board of directors of Innogenetics unanimously considered the offer to be friendly and supports it. The reference shareholders of Innogenetics (Rudi Mariën, Biovest CVA, Marigest Holding SA, S.A.T.E. SA, and Gengest BVBA), who jointly hold 18.48% of the shares of the Company, have committed to tender their shares to Solvay in the tender offer.

On June 3, Gen-Probe launched a counter-bid, raising the target price to EUR 6.10/share. On July 9, Solvay announced the increase of the offer to EUR 6.50/share. The same day Gen-Probe announced its withdrawal from bidding.

In view of the offer for Innogenetics, the Company has amended its by-laws. As a result of the decision taken by an extra-ordinary shareholders meeting paragraph 4 of Article 27 now reads as follows: "Every share has one vote, without prejudice of the limitations and exceptions provided by law. In the event of a tied vote, the proposal is rejected".

The offer period^{3,4} started August 12, and will run until September 5.

Based on information available from the CBFA, Solvay has increased its stake in Innogenetics, and owns 9.68% of the shares of Innogenetics. Apart from this increase in ownership of Innogenetics shares the Company is not aware of any other transaction between associated parties different from those as laid out in Note 20 of the 2007 annual brochure.

In view of the take-over bid, Innogenetics will not host a conference call.

1. Regulated information according to R.D. Nov. 14, 2007

2. Revenues include product sales, royalties, and license fees. The interim figures have not been audited.

3. The prospectus is available on the web site of Solvay: www.solvay.com

4. The Memorandum of Reply is available on http://www.innogenetics.com/memorandum_of_reply.html

Notes

1. Overview of occasional press releases in the first half 2008

January 18, the U.S. Appeals Court upheld finding that Abbott infringed Innogenetics' HCV Genotyping Patent, and ordered Abbott to pay Innogenetics monetary damages and sanctions.

On February 6, Innogenetics announced the granting of a key patent for hepatitis B drug resistance testing.
On February 12, Innogenetics announced the intention to restructure its subsidiary GENimmune.
On February 28, Innogenetics announced its new strategy, along with its full year 2007 financial results.
On March 27, Innogenetics achieved CE marking of 4-MAT™ HLA-A system, its first microarray test for clinical molecular diagnostics.
On April 8, Innogenetics and Solvay Pharmaceuticals extended collaboration for biomarker discovery.
On April 14, Innogenetics received US\$9.5m in settlement and licensing fees from Abbott Laboratories.
On April 25 Solvay Pharmaceuticals S.A. launched friendly bid to acquire Innogenetics.
On May 8, Innogenetics signed a collective labor agreement.
On May 26, Innogenetics announced implementation of GENimmune restructuring.
On May 30 GENimmune was definitively closed.
On June 2, a new HPV genotyping test received CE-mark.
On June 16, amendment article 27 of the by-laws accepted at extra-ordinary shareholders meeting.

2. Subsequent events

Innogenetics granted GlaxoSmithKline Biologicals a worldwide non-exclusive restricted license to use its proprietary SPF10 technology in clinical and epidemiological HPV vaccine studies. Innogenetics will receive royalties for each individual test performed during the studies.

3. Risk related to the business activities

The risks related to the diagnostics business have been outlined in the 2007 annual brochure, which is available on the internet at www.innogenetics.com/annualbrochures.html. The risks have not materially changed from those as laid out in the 2007 annual brochure.

4. Related party transactions

- Solvay, which is a shareholder of Innogenetics, announced on April 25 a friendly offer to acquire Innogenetics. This offer was increased on July 9.
- Based on information available from the CBFA, Solvay has increased its stake in Innogenetics, and owns 9.68% of the shares of Innogenetics.
- Apart from the above two elements the Company is not aware of any other transaction between associated parties different from those as laid out in Note 20 of the 2007 annual brochure. Disclosures in view of the Takeover Directive are outlined in the annual brochure under 5.2.5.

5. Accounting standards used and status of audit

All figures in the press release and corresponding tables are in EUR (in '000), except as otherwise stated. The figures and consolidated statements are in accordance with IFRS standards as currently adopted in the European Union. The statements are in compliance with IAS 34. The figures have not been audited. Due to rounding, some financial data may not apparently add-up in this management report or in the accompanying tables.

6. Declaration by responsible person (R.D., November 14, 2007)

CDW Invest BVBA, represented by Christiaan De Wilde, CEO, and WVC Consulting BVBA, represented by Walter Van Cauwenberge, CFO, declare that to the best of their knowledge:

- 1) the summary financial information prepared in conformity with the applicable accounting standards, gives a true and fair view of the financial situation and results of Innogenetics and its consolidated subsidiaries;
- 2) The intermediate report contains a faithful presentation of significant events occurring over the first six months of 2008, and as the case may be, major risks, uncertainties and transactions between related parties, and of their impact on the summary financial information.

Innogenetics further reported:

(i) Unaudited consolidated income statement first half 2008 (compared to 2007):

	6 months ended	
	30 June 2008	30 June 2007
<i>All figures in thousands EUR, except share amounts</i>		
<i>According to IFRS</i>		
Product sales	27 552	25 482
Royalties	1 916	1 895
License fees	1 158	22
Revenues	30 626	27 399
Cost of sales	(12 763)	(12 028)
Gross profit / (loss)	17 863	15 371
Grants received for Research and development	248	552
Research and development contract income	1 119	1 109
Research and development expenses	(10 405)	(13 961)
Research and development	(9 038)	(12 300)
Marketing and sales expenses	(7 310)	(7 919)
Administration expenses	(4 996)	(2 183)
Operating expenses	(12 306)	(10 102)
Operating profit /(loss) before restructuring & impairment losses	(3 481)	(7 031)
Restructuring & impairment losses	(8 032)	-
Operating profit / (loss) (EBIT)	(11 513)	(7 031)
Interest expenses	(1 786)	(1 483)
Interest income	375	554
Investment income and other	5 171	300
Other income / (expenses)	3 760	(629)
Profit / (loss) before taxes	(7 753)	(7 660)
Income taxes – (payable)/adjustment	(261)	(134)
Net profit / (loss)	(8 014)	(7 794)
Operating profit / (loss) before depreciation and amortization (EBITDA)	(2 200)	(2 475)
EPS from continuing operations (basic/diluted)	(0,26)	(0,25)
Shares used in computing per share amount (basic)	30 878 920	30 878 920
Shares used in computing per share amount (diluted)	30 880 072	30 878 920

(ii) Unaudited consolidated balance sheet on 30 June 2008 vs 31 December 2007:

	30 June 2008	31 December 2007
<i>All figures in thousands EUR, except share amounts</i>		
<i>According to IFRS</i>		
Current assets		
Cash and cash equivalents	15 665	23 478
Accounts receivable	18 127	19 060
Inventories	10 215	10 210
Other accounts receivable	2 042	1 621
Total current assets	46 049	54 369
Non current assets		
Intangible assets	25 050	30 597
Property, plant and equipment	18 019	19 600
Accounts receivable more than one year	357	359
Total non current assets	43 426	50 556
TOTAL ASSETS	89 475	104 925
Current liabilities		
Current instalments of long-term obligations	8 777	9 932
Trade accounts payable	7 292	8 798
Other current liabilities	15 136	14 579
Current tax liabilities	277	187
Total current liabilities	31 482	33 496
Non current liabilities		
Long-term obligations	36 054	41 039
Provisions	1 004	762
Other non-current liabilities	1 233	1 677
Total non-current liabilities	38 291	43 478
Shareholders equity		
Share capital	19 398	19 398
Issuance premium	163 096	163 070
Reserves	(1 762)	(1 501)
Retained earnings	(161 030)	(153 016)
Total shareholders equity	19 702	27 951
TOTAL LIABILITIES AND EQUITY	89 475	104 925

(iii) Unaudited consolidated statement of cash flows:

<i>All figures in thousands EUR</i>	6 months ended	
	30 June 2008	30 June 2007
CASH FLOWS FROM OPERATING ACTIVITIES		
Net Profit/(loss)	(8 014)	(7 794)
Depreciation, amortization and impairment results	9 313	4 556
Increase / (decrease) in provisions	242	(2 556)
Share-based payment	26	111
Gain on disposal of fixed assets	(124)	(7)
Loss on disposal of fixed assets	44	126
Interest paid	1 786	1 510
Interest received	(351)	(511)
(Increase) / decrease in accounts receivable	511	1 055
(Increase) / decrease in inventories	(5)	(2 002)
(Increase) / decrease in current tax assets	-	-
Increase / (decrease) in accounts payable	(1 506)	602
Increase / (decrease) in accruals and other liabilities	(878)	(2 514)
Increase / (decrease) in current tax liabilities	90	(156)
Increase / (decrease) in non-current liabilities	(442)	(216)
Total adjustments	8 706	(2)
Net cash used in operating activities	692	(7 796)
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of property, plant and equipment	(1 617)	(1 992)
Purchase of intangible assets	(489)	(1 245)
Net cash used in investing activities	(2 106)	(3 237)
CASH FLOWS FROM FINANCING ACTIVITIES		
Payments on long-term obligations	(7 182)	(4 427)
Proceeds from long-term obligations	1 043	1 438
Payments on notes payable to banks	-	(1 435)
Proceeds from notes payable to banks	-	-
Currency translation adjustment	(260)	(131)
Proceeds from issuance of convertible bond	-	31 700
Transaction costs	-	(1 036)
Net cash provided by / (used in) financing activities	(6 399)	26 109
Net increase / (decrease) in cash and cash equivalents	(7 813)	15 076
Cash and cash equivalents at beginning of year	23 478	22 349
Cash and cash equivalents at end of period	15 665	37 425

(iv) Unaudited consolidated statement of shareholders' equity

Movements during the six months of 2007

<i>All figures in thousands EUR</i>		Equity attributable to the equity holders of the Company				
	Number of shares issued	Share capital	Issuance premium	Retained earnings	Accumulated currency translation and fair value adjustments	Total shareholders ' equity
Total as per December 31, 2006	30 878 920	19 398	157 419	(135 639)	(856)	40 322
Currency translation adjustment					(131)	(131)
Net profit / (loss)				(7 794)		(7 794)
Recognition of share- based payment			110			110
Recognition of equity component of convertible bond			5 521			5 521
Total as per June 30, 2007	30 878 920	19 398	163 050	(143 433)	(987)	38 028

Movements during the six months of 2008

Total as per December 31, 2007	30 878 920	19 398	163 070	(153 016)	(1 501)	27 951
Currency translation adjustment					(261)	(261)
Net profit/(loss)				(8 014)		(8 014)
Recognition of share- based payment			26			26
Recognition of equity component of convertible bond						
Total as per June 30, 2008	30 878 920	19 398	163 096	(161 030)	(1 762)	19 702